Clinical Trial Search

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Clinical Benefit Rate — 22 Participants

Primary: 6-month Progression-free Survival Rate (PFS) — 12 participants

Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Progression-free Survival — 1.8; 3.7 months

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653

Primary: Tumor Best Response Rate — 0 Participants

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants

Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants

Primary: Objective Response Rate, Evaluated According to the RECIST Criteria — 0 participants